Intrexon | XON - Себестоимость





Себестоимость Изменить Дата
Agenus USD 642K 399K 2025-09
Alaunos Therapeutics USD 0 18K 2024-09
Amgen USD 1.79B 128M 2025-12
Anika Therapeutics USD 11.44M 797K 2025-12
AstraZeneca USD 3.27B 471M 2025-12
Bristol-Myers Squibb USD 4.92B 657M 2025-12
Gilead Sciences USD 1.62B 50M 2025-12
GlaxoSmithKline GBP 2.61B 377M 2025-12
Heron Therapeutics USD 11.12M 795K 2025-12
Incyte USD 121.18M 22.18M 2025-12
Intrexon USD 1.01M 344K 2024-06
Karyopharm Therapeutics USD 37.43M 2.41M 2024-09
Ligand Pharmaceuticals USD 11.9M 733K 2025-09
MacroGenics USD 10.12M 34.18M 2025-12
MannKind USD 33.65M 13.44M 2025-12
Merck USD 3.32B 531M 2025-12
Novartis USD 3.54B 3M 2025-12
Rigel Pharmaceuticals USD 8.03M 5.22M 2024-09
Roche Holding CHF 8.48B 4.61B 2025-12
Sangamo BioSciences 2.42M 1.11M 2024-06
Thermo Fisher Scientific USD 7.58B 674M 2025-12
Veracyte USD 39.28M 1.93M 2025-12
Xencor USD 61.66M 50.95M 2025-06